ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active proteases and other inflammatory biomarkers, today announces that it has appointed Hölzel Diagnostika as the first distributor of its portfolio of respiratory research assays in Europe.

Based in Cologne and founded in 1993, Hölzel Diagnostika specialises in the commercialisation of high-quality laboratory and research products in the DACH region countries of Germany, Austria and Switzerland. This partnership agreement enables them to add ProAxsis’ activity-based immunoassay kits for the quantification of the active forms of neutrophil elastase, proteinase 3 and cathepsin G to their extensive portfolio of more than six million products.

Speaking about the agreement, Dr David Ribeiro, CEO of ProAxsis, said: “Following close on the heels of our recent agreement with Diapharma for distribution rights in North America, we’re excited to finalise this agreement with Hölzel for another critically important geographical sales territory.  Hölzel has outstanding existing commercial relationships in place with more than 90% of all university and pharmaceutical company laboratories in the DACH region, providing access to our product portfolio for this key customer group.”

Christina Neumann, Product Manager at Hölzel Diagnostika, added: “We’re delighted to have gained access to the innovative ProteaseTag® technology of ProAxsis and look forward to providing our research laboratory customers in Germany, Austria and Switzerland with solutions for the specific quantification of these key protease biomarkers.”

Any enquiries concerning ProAxsis’ work with proteases and other inflammatory biomarkers can be directed to info@proaxsis.com. 

To learn more about Hölzel Diagnostika, please visit www.hoelzel-biotech.com.

ABOUT PROAXSIS

ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, and with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has developed activity-based immunoassays for the specific quantification of the active form of Neutrophil Elastase, Proteinase 3 and Cathepsin G, as potential biomarkers of lung infection and inflammation in chronic respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD), cystic fibrosis and bronchiectasis. 

This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels.  Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months.

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha.

Aside from the provision of assays, ProAxsis is able to offer a sample analysis service at its purpose-built laboratory facility in Belfast, and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.

ProAxsis became a fully owned subsidiary of Netscientific plc in October 2020. 

ABOUT HÖLZEL DIAGNOSTIKA

Hölzel Diagnostika is your partner when it comes to high quality products for your laboratory and research. The company offers more than six million products from well-known and international manufacturers from over 20 countries.

Hölzel Diagnostika offers you an individual service, so that you can quickly and easily receive your required products, even if we have not listed them yet.

Additionally 90% of all DACH universities and pharmaceutical companies have negotiated individual conditions and discounts.

27 years as a Life Science Distributor on the market have given Hölzel Diagnostika a wealth of experience and expertise in various fields. Since their foundation, reliability, interest and commitment have been the key to Hölzel Diagnostika’s success.